[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-327764-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-327764-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","application-of-nitroxoline-in-urologic-oncology-a-review-of-evidence","Application of nitroxoline in urologic oncology - a review of evidence","","Urologic cancers show persistent high incidence and mortality, creating an urgent demand for effective, safe therapies. Because conventional chemotherapy is limited by toxicity, evolving multidrug resistance, and complex multifocal spread, drug repurposing offers a faster and more cost-effective pathway. Nitroxoline (NIT), a decades-established medication with a well-characterized pharmacokinetic profile used for uncomplicated urinary tract infections, is evaluated for oncologic potential. The review synthesizes available studies on NIT’s anti-angiogenic, anti-invasive, anti-metastatic and resistance-modulating effects, while noting variability across cell lines and emphasizing further research needs.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/application-of-nitroxoline-in-urologic-oncology-a-review-of-evidence/327764/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/application-of-nitroxoline-in-urologic-oncology-a-review-of-evidence/327764.png","ImageObject",300,407,{"name":42,"@type":43},"Ivy","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is drug repurposing a compelling strategy for urologic cancers?","Question",{"text":63,"@type":64},"Repurposing allows use of drugs with known safety profiles, which can reduce the cost and time required to develop new treatments. It also addresses limitations of conventional chemotherapy such as toxicity and drug resistance.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is nitroxoline (NIT) and why is it relevant to urologic oncology?",{"text":68,"@type":64},"Nitroxoline is an established drug with a well-described pharmacokinetic profile that has been used for uncomplicated urinary tract infections. The review focuses on urologic cancers where its excretion characteristics may be advantageous.",{"name":70,"@type":61,"acceptedAnswer":71},"What effects has nitroxoline shown in the reviewed evidence?",{"text":72,"@type":64},"Across available studies, NIT has demonstrated effectiveness in inhibiting angiogenesis, tissue invasion, and metastasis formation, and in counteracting multidrug resistance. Reported efficacy and mechanisms vary between different cell lines.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},327764,1790444978,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":111,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":118},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","The persistence of high incidence and mortality rates associated with urologic cancers underscores the urgent need for effective and safe treatments. Conventional chemotherapy regimens are often limited by their high toxicity, the cancer’s drug resistance, and the challenge of managing independently evolving multifocal spread. In this context, a repurposing strategy is particularly enticing. It allows for the introduction of a drug with a known safety profile, thus significantly reducing the costs and time necessary to introduce a new treatment. Nitroxoline (NIT), a drug with a well-established pharmacokinetic profile known for over 50 years and utilised in treating uncomplicated urinary tract infections, has recently garnered attention for its potential oncologic applications. Given the pharmacokinetic properties of NIT, our focus was specifically on urologic cancers in which its excretion profile is most advantageous. We examined all available studies, demonstrating significant effectiveness of NIT in inhibiting angiogenesis, tissue invasion, metastasis formation, and counteracting multidrug resistance. The efficacy and mechanism of action of NIT were found to vary across different cell lines. The findings to date are promising, suggesting that NIT or its derivatives could play a role in oncology, although further research is necessary to fully understand its potential and applicability in cancer treatment.  \nKey words: bladder cancer, prostate cancer, oncology, nitroxoline.  \nContemp Oncol (Pozn) 2024; 28 (1): 1–8 DOI: [https://doi.org/10.5114/wo.2024.139584](https://doi.org/10.5114/wo.2024.139584)  \nReview paper  \nApplication of nitroxoline in urologic oncology – a review of evidence  \nWojciech Andrzej Tomczak1, Wojciech Krajewski2, Joanna Chorbińska2,Łukasz Nowak2, Jan Łaszkiewicz1, Katarzyna Grunwald1, Adam Chełmoński1, Szymon Pisarski1, Tomasz Szydełko1  \n1University Centre of Excellence in Urology, Wrocław Medical University, Wrocław, Poland 2Department of Minimally Invasive and Robotic Urology, University Centre of Excellence in Urology, Wrocław Medical University, Wrocław, Poland  \nIntroduction  \nCancer-related mortality represents the second leading cause of premature death globally, with its incidence rising steadily – from 5.6 million cases in 1990 to 10.8 million in 2019 [1] . In the United States alone, the year 2023 is expected to see 609,820 deaths and nearly 2.0 million new cancer diagnoses [2] . This escalating issue has catalysed a surge in the exploration of novel treatment strategies. A notable approach is the concept of drug repurposing, wherein established pharmaceuticals, previously utilised in distinct medical domains, are being reassessed for their efficacy, in this case in oncology. This methodology is particularly advantageous due to the well-documented safety profiles and the established spectrum of side effects of these drugs, a critical consideration given the typically high toxicity associated with oncological therapies [3] . In this realm, the antibiotic nitroxoline (NIT), initially introduced in the 1960s, has emerged as a compound of significant interest, demonstrating potential therapeutic benefits in the treatment of cancer [4] . Currently, the potential for NIT as a treatment option is being explored across various cancers, including ones originating from the bladder, prostate, pancreas, lungs, brain, and other sites [5–10] . This review investigates the use of NIT in urologic cancer treatment, discusses potential adverse effects, and digs into specific mechanisms of action within the framework of urologic oncology.  \nMaterial and methods  \nIn this systematic review, we present a comprehensive analysis of the therapeutic potential of NIT in urologic oncology, underscored by strict adherence to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines and the population, intervention, comparison, and outcome (PICO) framework. We formulated the following PIC","cbCaikB2PLge8BHl","https://ap.wps.com/l/cbCaikB2PLge8BHl","pdf",96534,"English","# Introduction\n# Material and methods\n## Safety of administration\n# Identification of studies via databases and registers\n# Efficacy and mechanisms of action","[{\"question\":\"Why is drug repurposing a compelling strategy for urologic cancers?\",\"answer\":\"Repurposing allows use of drugs with known safety profiles, which can reduce the cost and time required to develop new treatments. It also addresses limitations of conventional chemotherapy such as toxicity and drug resistance.\"},{\"question\":\"What is nitroxoline (NIT) and why is it relevant to urologic oncology?\",\"answer\":\"Nitroxoline is an established drug with a well-described pharmacokinetic profile that has been used for uncomplicated urinary tract infections. The review focuses on urologic cancers where its excretion characteristics may be advantageous.\"},{\"question\":\"What effects has nitroxoline shown in the reviewed evidence?\",\"answer\":\"Across available studies, NIT has demonstrated effectiveness in inhibiting angiogenesis, tissue invasion, and metastasis formation, and in counteracting multidrug resistance. Reported efficacy and mechanisms vary between different cell lines.\"}]","Application of nitroxoline in urologic oncology - a review of evidence | PDF",1789977990]